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Background: Today, intra-articular bupivacaine injections are common practice, with very good 
analgesic effects. This method of analgesia is utilized by general practitioners, orthopedic surgeons 
and anesthesiologists. Unfortunately, since 2004, more than 200 cases of chondrolysis were noted 
following intra-articular bupivacaine infusion. Numerous studies have investigated the safety of 
intra-articular bupivacaine. The aim of this thesis was to quantify the risk of chondrolysis with 
intra-articular bupivacaine and to guide medical practitioners in safe practice. 
 
Methods: A literature review was done of the most recently published original research, meta-
analysis and review articles. Adverse outcomes were mostly associated with bupivacaine infusions, 
rather than with single intra-articular doses of bupivacaine. Limited data on the safety of a single 
dose of intra-articular bupivacaine was found. We conducted a pilot study to investigate the safety 
of a single dose of intra-articular bupivacaine.  A paired, case-controlled, experiment was done 
using four merino sheep.  The nul hypothesis was that a single dose of intra-articular bupivacaine 
did not cause chondrolysis when compared with a dose of intra-articular normal saline. Our results 
were added to the thesis to further quantify the risk. 
 
Results: Numerous in vitro and in vivo studies confirmed that bupivacaine is chondrotoxic. The 
chondrotoxic effect is time, dose and concentration dependent. Our pilot study revealed that single 
dose intra-articular bupivacaine may also be unsafe for chondrocytes. 
   
Conclusion: The administration of intra-articular bupivacaine is toxic to chondrocytes. The 
chondrotoxic effect of intra-articular bupivacaine is time, dose and concentration dependent. 
Infusions of intra-articular bupivacaine should be contra-indicated. From the limited data available 
on single dose intra-articular bupivacaine, it appears that it is also chondrotoxic. Magnesium, 
morphine and clonidine may be safer for intra-articular use, but this needs further investigation. 













Agtergrond: Vandag word bupivacaine gebruik as intra-artikulêre inspuiting met baie goeie 
analgetiese effek. Hierdie metode word ontgin deur, onder andere, algemene praktisyns, ortopediese 
chirurge en anestesioloë.  Sedert 2004 is meer as 200 gevalle van chondrolise aangeteken na die 
toediening van intra-artikulêre bupivacaine infusies. Talle studies het gevolg om die veiligheid van 
intra-artikulêre bupivacaine te ondersoek.  Die doel van hierdie skripsie is om die risiko verbonde 
aan intra-artikulêre bupivacaine te kwantifiseer en aan mediese praktisyns veilige riglyne te stel.    
 
Metode: ‘n Literatuur oorsig is gedoen, insluitende die mees onlangs gepubliseerde oorspronklike 
navorsing, meta-analises asook oorsig artikels.  Ongunstigde uitkomstes is meestal geassosieer met 
intra-artikulêre bupivacaine infusies, eerder as met enkel dosering intra-artikulêre bupivacaine.  
Beperkte data met betrekking tot die gebruik van bupivacaine as enkel dosering intra-artikulêr is 
beskikbaar. Om die veiligheid van enkel dosering intra-artikulêre bupivacaine te ondersoek is ‘n 
loodsstudie gedoen. Dit is ‘n gevalle-kontrole in-vivo eksperiment, met vier merino skape.  Die nul 
hipotese is dat ‘n enkel dosering intra-artikulêre bupivacaine nie meer chondrolise veroorsaak, as ‘n 
enkel dosering intra-artikulêre normale saline nie. Die resultate is ingesluit as deel van die stawende 
data om die risiko te kwantifiseer. 
 
Resultate: Talle in-vitro asook in-vivo studies het bevestig dat bupivacaine chondrotoksies is.  Die 
toksiese effek is tyd, dosis en konsentrasie afhanklik. Ons loodsstudie het ook getoon dat enkel 
dosering intra-artikulêre bupivacaine moontlik skadelik vir kraakbeen kan wees. 
 
Gevolgtrekking: Die toediening van intra-artikulêre bupivacaine is toksies vir chondrosiete.  Die 
chondrotoksiese effek is tyd, dosis en konsentrasie afhanklik. Infusies van intra-artikulêre 
bupivacaine is dus gekontraïndikeer.  Die beperkte data oor enkel dosering intra-artikulêre 
bupivacaine dui ook moontlik chondrotoksisiteit aan.  Magnesium, morfien en clonidine kan 
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The aim of this thesis is to review the literature on the effect of intra-articular bupivacaine on 
chondrocytes. As most of the adverse outcomes were associated with intra-articular bupivacaine 
infusions, the effect of a single dose of intra-articular bupivacaine on chondrocytes was further 
investigated by conducting a pilot study on four adult merino sheep. The literature review will be 
discussed in chapter 1 of this thesis and the results of the pilot study will be disclosed in chapter 2, 
followed by a discussion of our findings and a conclusion in chapters 3 and 4 respectively. We trust 
that it will give more insight and guidance into the safe practice of intra-articular bupivacaine. 
 
WJ van der Merwe 
Registrar 
Department of Anesthesiology and Critical Care 


























LITERATURE REVIEW: INTRA-ARTICULAR BUPIVACAINE 
 





Today, intra-articular bupivacaine injections are common practice amongst orthopedic surgeons, 
general practitioners and anesthetists with very good analgesic effects.1-2 
 
This method of pain control is utilized in the outpatient, inpatient and perioperative setting. 
Bupivacaine has been used either as the sole drug of the injectate, or in combination with additives 
such as clonidine, opiates, corticosteroids and epinephrine.3 
 
This practice of analgesia has however not been without local risks to joints. There are even reports 
of possible systemic toxicity following intra-articular administration of bupivacaine.4-5 
 
According to Meining et al.6, peak plasma levels after therapeutic intra-articular dosages occur 
approximately 20 minutes after administration, but the actual plasma level is normally eight to ten 
times less than the human convulsion threshold. Certain surgical techniques compromising the 
cartilage and bone structure might increase the risk of systemic uptake.6 However, the reported 
incidence of systemic compromise after intra-articular bupivacaine is extremely low.  
 
More prevalent and of greater concern, are reports of a possible chondrotoxic effect of intra-
articular bupivacaine, especially in cases of intra-articular infusion.7-9 
 
Between 2004 and 2012 more than 200 cases of chondrolysis were noted following intra-articular 
bupivacaine infusion. The mean age of the patients who developed chondrolysis was only 30 years, 
suggesting bupivacaine as the possible cause.11 In a series of 19 patients who received intra-articular 
infusions of bupivacaine and epinephrine, 12 developed chondrolysis. 10 
 
Numerous in vitro and in vivo studies have investigated the safety of intra-articular bupivacaine to 
chondrocytes. 
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1.2 IN VITRO STUDIES 
 
Drogoo et al.13 claimed that intra-articular bupivacaine infusions could be utilized with the 
provision that the infusion duration did not exceed 48 hours. Interestingly, they found that 
bupivacaine in combination with epinephrine caused significantly more chondrotoxicity than 
bupivacaine alone. Human chondrocytes, cultured in a bioreactor that mimicked synovial 
metabolism, were exposed to 1% lidocaine, and 0.25% and 0.5% bupivacaine. Chondrocytes were 
exposed to these solutions alone and with epinephrine. Cell viability was assessed 24, 48 and 72 
hours after continuous infusion. Similar chondrocyte necrosis was found in 0.25% and 0.5% 
bupivacaine groups at 24 and 48 hours when compared to control groups. When epinephrine was 
added, significantly greater necrosis was seen (p < 0.05) at all intervals. At 72 hours, the 0.5% 
bupivacaine alone had caused significant necrosis.13 
 
Lo et al.14 confirmed the chondrotoxic effect of 0.25% bupivacaine, 1% lidocaine and 0.5% 
ropivacaine on bovine cartilage, which had been sampled from the radial-carpal joint. Significantly 
worse chondrotoxicity was shown with longer periods of exposure of the cartilage to the local 
anesthetics.14 
 
Hennig et al.15 found intra-articular bupivacaine 0.5% to be toxic to canine cartilage.15 
 
Baker et al.16 compared the effect of different local anesthetics at different concentrations on human 
chondrocytes.  Cells were exposed to levobupivacaine (0.13%, 0.25%, 0.5%), bupivacaine (0.13%, 
0.25%, 0.5%), ropivacaine (0.19%, 0.38%, 0.75%), normal saline and 10% magnesium sulphate, for 
15 minutes each. After 24 hours, cell viability was found to be significantly decreased in all local 
anesthetic groups and appeared to be concentration dependent (p < 0.05). There was no reduction in 
chondrocyte viability after exposure to 10% magnesium sulphate.16  
 
Wang et al.17 evaluated chondrocyte viability and chondrocyte function after exposure to 
bupivacaine. They used an intervertebral disc organ model, which they harvested from 10 week old 
mice. They waited 3 days before exposing the cells to bupivacaine to compensate for surgically 
induced inflammatory responses. The cells were exposed to bupivacaine 0.1%, 0.25% and 0.5%, for 
60 minutes. The 0.5% bupivacaine group was also exposed for different time periods of 30, 60 or 
120 minutes. Cell viability, collagen synthesis and proteoglycan matrix synthesis was evaluated. 
They showed a dose and time dependent reduction in cell viability. Bupivacaine 0.5% killed 20% of 
chondrocytes after 60 minutes and up to 70% after 120 minutes (95% CI 53.2 – 70.1%). 
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Bupivacaine 0.5% reduced the proteoglycan matrix synthesis three-fold and collagen synthesis four-
fold. The authors postulate that the reduced synthetic function that was demonstrated may only be a 
reflection of chondrocyte loss, and not necessarily reflect an inhibition of chondrocyte function by 
bupivacaine.17 
 
Breu et al.18 attempted to quantify bupivacaine's chondrotoxic effect on human mesenchymal cells, 
and compared it to equipotent concentrations of mepivacaine and ropivacaine. After 60 minutes of 
exposure to the local anesthetics, bupivacaine was found to be significantly more chondrotoxic, 
reducing cell viability by 5% (± 1%) when compared to mepivacaine's 1% (± 0%) reduction. 
Ropivacaine proved to be the least toxic.18 
 
Beyzadeoğlu et al.19 showed that both bupivacaine and its enantiomer, levobupivacaine, were 
chondrotoxic to rat cartilage.  Levobupivacaine proved to be more toxic.19 
 
In contrast, Erden et al.20 could not illustrate any increase in inflammation in articular and peri-
articular surfaces in a rat model after treatment with levobupivacaine. The authors advocated that 
levobupivacaine might therefore be a safe alternative.20 A possible cause for their negative results, 
might be that the samples were only investigated up to 21 days post intervention, and the changes 
become more prevalent at longer intervals after exposure.11 
 
In an experiment done by Gungor et al.21, no statistical difference in chondrocyte apoptosis could be 
demonstrated between bupivacaine and levobupivacaine.21 
 
Most of the in vitro studies were not done on full thickness cartilage and therefore might falsely 
increase the likelihood of positive results.  It is also problematic to make assumptions based on in 
vitro cell cultures.  The complexity of the synovial environment, extracellular collagen and 
proteoglycan matrix interactions can only be mimicked to a certain degree, before compromising 
the true milieu.  In vivo studies have therefore also been done.  
 
1.3 IN VIVO STUDIES 
 
Gomoll et al.12 divided 30 male New Zealand white rabbits into three groups, to receive either 
normal saline, bupivacaine 0.25% or bupivacaine 0.25% with epinephrine (1:200 000), via 
continuous infusion into their glenohumoral joints for 48 hours at a rate of 210μL/h. This dosage 
was proportional to the normal infusion rate of 4ml/h administered to adult human patients. 
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Cartilage samples from the glenohumeral joints were taken after one week and chondrocyte 
viability was evaluated by measuring metabolic sulfate uptake. Sulfate uptake was decreased by 
16%, 58% and 53% in the different groups respectively when compared to their control shoulders. 
The bupivacaine and bupivacaine with epinephrine groups had 50 % (p = 0.02) and 56% (p = 0.009) 
greater reduction in sulfate uptake when compared to normal saline. The addition of epinephrine did 
not cause a statistical difference between the two bupivacaine groups. The authors therefore 
cautioned against the use of continuous infusion of bupivacaine into joints.12 
 
Three years later, in 2009, Gomoll et al.22 performed another in vivo study on 36 rabbits. They were 
randomly infused for 48 hours into their glenohumoral joints with either normal saline, bupivacaine 
(0.25%) or bupivacaine (0.25%) with epinephrine. After 3 months, chondrocyte viability was 
assessed by measuring proteoglycan synthesis and conventional histology.  There were no 
significant differences amongst the groups in cell count, cell viability and histology results.  Gomoll 
claims that an additional noxious stimulus might be necessary for permanent damage.22 The critique 
to this study, based on the work of Drogoo et al.13, would be that infusions were not extended 
beyond 48 hours.13 
 
After all the alarming results of the studies with local anesthetic infusions, the question of the safety 
of a single dose of intra-articular bupivacaine was raised. Chu et al.23 performed an in vivo study on 
48 rats, that had 0.9% saline injected into their stifle joints, and either 0.5% bupivacaine or 0.6% 
mono-iodoacetate injected into their contralateral stifle joints. The mono-iodoacetate served as a 
positive control due to its known chondrotoxicity. Histological analyses of the chondrocytes were 
done at one week, four weeks, twelve weeks and six month intervals. Cell viability and cell density 
were quantified and the histology was interpreted with the Modified Mankin Score (see Table 2.1). 
A 50% reduction in chondrocyte density was found in the bupivacaine group when compared to its 
contralateral saline group (p < 0.01) at six months. They also showed that acute loss of 75% of 
viable chondrocytes resulted in severe progressive arthritis after 6 months. It was more prominent 
after longer intervals since administration.23 
 
This delayed arthritic effect seen in the rats compared well with human case studies, in whom 
symptoms were noticed between 2 to 8 months after exposure to bupivacaine. A possible reason for 
this delayed onset of arthritis was postulated by Matsen et al.11, who suggested that an initial 
reduction of viable chondrocytes later resulted in poorer maintenance of matrix integrity. 
Alterations in mitochondrial DNA also led to delayed chondrocyte apoptosis.11 
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Chu et al.23 emphasized that single dose intra-articular bupivacaine needed more investigation, 






































A CASE CONTROLLED EXPERIMENT TO EVALUATE THE IN VIVO EFFECTS OF 
SINGLE DOSE INTRA-ARTICULAR 0.5% BUPIVACAINE ON CARTILAGE OF SHEEP 
 
2.1 INTRODUCTION 
It is difficult to extrapolate data from rats to the human race, because articular biomechanical 
differences exist between species, and simulation of therapeutic dosages of local anesthetics may be 
imprecise. The ovine stifle joint has been used increasingly in experimental studies because of its 
similarities to the human knee. Besides minor differences, such as a smaller trochlear width and a 
narrower femoral intercondylar notch, the articular surfaces and biomechanics are very similar.24 
According to Osterhoff et al.24, the ovine stifle joint can be assumed to be approximately a third of 
the adult human knee in size. 
 
 
   Stifle joint 
 
         Knee joint 
Fig 2.1: Illustration of the stifle and knee joints used 
 
 
With the question concerning the safety of single dose intra-articular bupivacaine not yet clarified, 
we conducted a pilot study to simulate a single dose of intra-articular 0.5% bupivacaine on four, 18 
month old, merino sheep. The study was a case-controlled experiment and was unpaired, as each 
sheep was its own control. The nul hypothesis was that a single dose of intra-articular bupivacaine 
did not cause chondrolysis when compared with intra-articular normal saline. Ethics approval was 
obtained from the University of Stellenbosch Research Ethics Committee (SU-ACUM13-00004). 
The project was funded by the Harry Crossley Foundation. 
 





The animals were fasted for 8 hours prior to the experiment in order to reduce gastro-oesophageal 
reflux and aspiration risks during the sedation that was given. The sheep were sedated with intra-
muscular ketamine 5mg/kg. 
 
In the front legs, the right knee was injected with 7ml 0.5% bupivacaine, while 7ml 0.9% saline was 
injected into their left knee. This supra-normal dosage was the maximum amount which would fill 
the joint cavity without increasing intra-articular pressure. The knee cavity of the front leg is 
considerably smaller than the stifle joint.  This dosage addressed the question whether a single intra-
articular high dose of bupivacaine can cause significant chondrolysis. 
 
In the hind legs, 7ml 0.5% bupivacaine was given in the right stifle joint, while 7ml 0.9% saline 
was given in the left stifle joint. This was approximately a third of the volume usually administered 
to human adult knees. This dosage was comparable to that given to humans in the clinical setting 
and investigated whether a single, therapeutic dosage causes significant chondrolysis. 
 
The injections were done according to the same sterility protocols used in humans, to reduce the 
risk of intra-articular sepsis. Their pulse and breathing patterns were monitored until fully awake, 
and supplemental oxygen was administered throughout the procedure to keep their oxygen 
saturation above 90%. The animals were observed for the following 5 days for any acute 
complications of intra-articular injections, such as haemarthrosis and septic arthritis. (See Appendix 
A for example of monitoring sheet.) After the observation period, the animals were allowed to roam 
freely in camps on a farm for 6 months. This was to mimic a normal mobile functional human 
being. When the total of 6 months had expired the animals were taken back to the animal unit for 
sampling of their joint cartilage. Ketamine 5mg/kg intra-muscularly was given as a premed. 
Intravenous access was obtained and the animals were given an intravenous dosage of thiopentone 
10mg/kg, and a muscle relaxant, pancuronium 0.2mg/kg, followed by a lethal dose of potassium 
chloride 100mg/kg to serve as cardioplegia. After asystole was sustained and the sheep were 
declared dead, the knee and stifle joints were collected for histological evaluation of the cartilage. 
 
Cartilage was graded according to the Modified Mankin Score. The parameters used by the 
Modified Mankin Grading System are surface integrity, cellularity, cell cloning and safranin-O 
staining intensity (safranin-O binds stoichiometrically to chondroitin 6-sulphate and keratin 
sulphate in cartilage tissue sections). A higher score implicates more damage to chondrocytes. 
Stellenbosch University  https://scholar.sun.ac.za
8 
 
These parameters gave each sample a score out of 23 as described below in table 2.1: 
Table 2.1:  Modified Mankin Score 
ARTICULAR SURFACE INTEGRITY SCORE 
Normal 0 
Slight surface irregularities 1 
Moderate surface irregularities 2 
Severe surface irregularities 3 
Clefts to transitional zone 4 
Clefts to radial zone 5 
Clefts to calcified zone 6 
Fibrillation and/or loss to transitional zone 7 
Fibrillation and/or loss to radial zone 8 
Fibrillation and/or loss to calcified zone 9 
Fibrillation and/or loss to subchondral zone 10 
CELLULARITY  
Normal 0 
Slight focal decrease 1 
Moderate decrease 2 
Severe decrease (50% of cells) 3 
Complete loss of cells 4 
CLONE FORMATION  
None 0 
Several doublets 1 
Many doublets 2 
Doublets and triplets 3 
Multiple cell nests 4 
SAFRANIN-O STAINING  
Normal 0 
Slight reduction 1 
Reduction in radial layer 2 
Reduction in inter-territorial layer 3 
Only present in peri-cellular matrix 4 
No staining 5 
TOTAL 23 
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In the front knee joints, 5 cartilage biopsies were taken as illustrated in figure 2.2:  
1. os carpi ulnare 
2. os carpi intermedium 
3. os carpi radiale 
4. os carpale quartum 
5. os carpale tertium 




Fig 2.2:  Anatomy of the knee of domestic animals33 
 
In each stifle joint, 15 cartilage biopsies were taken from 15 predetermined, anatomically distinct 
positions as illustrated in figure 2.3: 
1. anterior patella 
2. posterior patella 
3. anterior femoral groove 
4. central femoral groove 
5. posterior femoral groove 
6. anterior lateral femoral condyle 
7. posterior lateral femoral condyle 
8. anterior medial femoral condyle 
9. posterior medial femoral condyle 
10. anterior lateral tibial plateau 
11. posterior lateral tibial plateau 
12. central lateral tibial plateau 
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13. anterior medial tibial plateau 
14. posterior medial tibial plateau 
15. central medial tibial plateau 
 
Fig 2.3:  Anatomical predetermined positions for sampling of the stifle joint25 
 
This sampling method and sites were similar to that used by HR Moody et al.25 Each stifle joint was 
then given the total score from the 15 samples. 
 
In order to do the histological analysis, thin sections of the biopsied cartilage were made with a 
sharp trimming blade. The tissue sections were placed in correctly labeled histology cassettes with 
appropriate perforations for tissue processing. Processing in graded alcohols and formaldehyde was 
done using the Shandion Elliot Duplex processor overnight for 17 hours. This was followed by 
orientating the tissue sections within a mould, which was filled with liquid paraffin wax using the 
Leica EG 1160 embedder. Once the liquid wax was set and the cassettes were trimmed to expose 
the tissue, tissue sections of approximately 6μm were cut using a Leica TM2125RT microtome. Two 
sections were cut from one cassette and placed on two different glass slides. The sections were 
placed in an incubator for approximately 2 hours prior to staining with hematoxylin and eosin 
(H&E) using a Leica Autostainer XL. The safranin-O special stain was performed at a later stage. 
For this stain, the sections were de-paraffinized and hydrated in different graded alcohols (100%, 
95%, and 70%) for one minute each. The sections were subsequently stained with Weigert’s iron 
hematoxylin solution for 10 minutes, followed by a 10 minute washing step using running tap 
water. Fast green (FCF) solution was used to stain the sections for 5 minutes after which 1% 
(glacial) acetic acid was used to rinse the sections for a maximum of 15 seconds. The sections were 
then placed in 0.1% safranin-O solution for 5 minutes before dehydrating the sections in graded 
alcohols. Cover slips were added using a mounting medium, in this case, DPX (Merck, Germany). 
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The slides were viewed with an Axioskop Zeiss light microscope and microphotographs were 
obtained using an attached Zeiss Axiocam camera. 
 
The right front knees formed the experimental group 1, and were compared to the left front knees, 
which was our control group 1. The right stifle joints formed experimental group 2, and were 
compared to the left stifle joints, which was our control group 2. Figure 2.4 is a diagram illustrating 












Figure 2.4:  Diagram of pilot study 
 
2.3 RESULTS 
2.3.1 SUPRA-NORMAL SINGLE DOSE IN KNEE JOINTS 
 
As described above, 5 samples were taken from each knee joint, namely:  
1. os carpi ulnare 
2. os carpi intermedium 
3. os carpi radiale 
4. os carpale quartum 
5. os carpale tertium. 
Each one of these biopsies was graded individually by the Modified Mankin Score.  From Sheep 2, 
the right os carpale quartum sample was insufficient for histological analysis.  The contralateral 
(left) os carpale quartum sample from Sheep 2 was therefore also excluded from the data. 
  
Table 2.2 summarizes the Modified Mankin Scores that was found in the knee joints. (See Appendix 
4 Adult Merino 
Sheep 
8 Knee Joints: 
Supra-normal 
dosage 




4 Left: 7ml 0.9% 
normal saline 
(Control group 1) 
 
4 Left: 7 ml 0.9% 
normal saline 
(Control group 2) 
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B for full details of the Modified Mankin Scores of the knee joints.) The total scores indicated in 
table 2.2 are the totals including all 5 samples from each joint.  In Sheep 2 it is the total of the 




Total Score Comparisons Right Knee Left Knee 
Sheep 1 21 17 
Sheep 2 14 21 
Sheep 3 35 16 
Sheep 4 17 22 
Totals 87 76 
Total Average Score per joint 21.75 19 
Average Score per biopsy 4,58 4 
 
From the data above, one can see that the total scores of the right joints (bupivacaine group) was 
slightly more than the left joints (saline group).  The data’s distribution was not symmetric and 
Somers’ D statistic was therefore used for statistical analysis to account for possible correlation 
between measurements from the same sheep.  The left joints, or the saline group was used as the 
reference. A positive coefficient indicates higher scores in the right joints (bupivacaine group).  
Fisher’s z transformation was applied on symmetric confidence intervals to obtain asymmetric 
confidence intervals.  Standard errors were obtained using the Jackknife method.33 Below is the 
analysis of the Modified Mankin Scores that was found in the knee joints.  
 
Table 2.3 
Modified Mankin Score 
Knee joints 
   
Coefficient 95% Confidence 
Interval 
P Value Jackknife 
Standard Error 




There was a 5.49% increase in Modified Mankin Scores for the bupivacaine group. As the 95% 
confidence interval includes zero, one must statistically assume that there is no statistical difference 
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between the groups. 
 
Figure 2.5 is a photo taken from a biopsy of a saline injected joint, illustrating normal surface 
integrity, normal cellularity with only minimal cloning present in the form of doublets: 
 
 
Fig. 2.5: Sheep 3; os carpale tertium, left knee joint 
 
In contrast, figure 2.6 is a biopsy from a bupivacaine injected joint, with severe degenerative 
changes. Note the surface irregularity, decrease in cellularity and cloning formation in the form of 
doublets and triplets. 
 
 
Fig. 2.6: Sheep 3; os carpi ulnare, right knee joint 
 
Differences in safranin-O staining were also observed. Safranin-O normally stains the nuclei black, 
the cytoplasma blue to green, and the cartilage, mucin and mast cell granules orange to red. Figure 
2.7 is an example of normal safranin-O staining: 
 




Fig. 2.7: Sheep 3; os carpi ulnare, left knee joint 
 
In contrast, figure 2.8 shows a picture of the contralateral, bupivacaine injected, knee of the same 
sheep. The safranin-O staining is visibly reduced. 
 
Fig. 2.8: Sheep 3; os carpi ulnare, right knee joint 
 
The different parameters of the Modified Mankin Score were also analysed individually. Tables 2.4, 
2.5, 2.6 and 2.7 include the results that were found concerning the articular surface integrity, 
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From the data above, the greatest difference was seen with articular surface integrity, with an almost 
30% reduction in articular surface integrity in the bupivacaine group. The p value was also the 
lowest at 0.252 for this parameter, but as the 95% confidence interval still includes 0, a significant 
difference cannot be concluded.  Interestingly, analysis of the safranin-O staining resulted in a 
negative coefficient, indicating a 5% decreased safranin-O staining in the saline group. 
 
 
2.3.2 THERAPEUTIC SINGLE DOSE IN STIFLE JOINTS 
 
As described in the methodology, 15 samples were taken from each stifle joint, namely; 
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1. anterior patella 
2. posterior patella 
3. anterior femoral groove 
4. central femoral groove 
5. posterior femoral groove 
6. anterior lateral femoral condyle 
7. posterior lateral femoral condyle 
8. anterior medial femoral condyle 
9. posterior medial femoral condyle 
10. anterior lateral tibial plateau 
11. posterior lateral tibial plateau 
12. central lateral tibial plateau 
13. anterior medial tibial plateau 
14. posterior medial tibial plateau 
15. central medial tibial plateau 
Each one of these biopsies was graded individually by the Modified Mankin Score.  From Sheep 1, 
the biopsy taken from the right posterior lateral tibial plateau was insufficient for histological 
analysis.  The contralateral (left) posterior lateral tibial plateau sample from Sheep 1 was therefore 
also excluded from the data. 
  
Table 2.8 summarizes the Modified Mankin Scores that were found in the stifle joints. (See 
Appendix C for full details.) The total scores are the totals including all 15 samples from each joint.  
In Sheep 1 it is the total of the remaining 14 valid samples.  The average scores per joint and sample 
were also calculated. 
 
Table 2.8 
Total Score Comparisons Right Stifle joint Left Stifle joint 
Sheep 1 31 33 
Sheep 2 57 78 
Sheep 3 81 45 
Sheep 4 68 65 
Totals 237 221 
Total Average Score per joint 59.25 55.25 
Average Score per biopsy 4.02 3.75 




As seen with the supra-normal dosage of intra-articular bupivacaine in the knee joints, we also 
found higher total Modified Mankin Scores in the bupivacaine group as compared to the normal 
saline group, with a therapeutic dosage of intra-articular bupivacaine. Somers’ D statistic was again 
used to analyse the Modified Mankin Scores as well as the individual parameters. Tables 2.9 – 2.13 
contain the statistical analysis of the data. 
 
Table 2.9 
Modified Mankin Score 
Stifle joints 
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An increase of 7% in the Modified Mankin Score was found in the bupivacaine injected right stifle 
joints, as compared to the saline injected left stifle joints. Figure 2.9 shows an example of a biopsy 




Fig. 2.9: Sheep 1; central lateral tibial plateau, left stifle joint 
 
To illustrate the differences observed in the parameters of the Modified Mankin Score, figure 2.10 
from a bupivacaine injected right stifle joint, shows an irregular articular surface with abnormal 
cellularity and clone formation in the form of doublets. 
 




Fig. 2.10: Sheep 2; central medial tibial plateau, right stifle joint 
 
These degenerative changes were not only limited to our bupivacaine group.  The sample illustrated 
in figure 2.11 below, was taken from the left stifle joint in sheep 2 (saline group) and shows severe 




Fig. 2.11: Sheep 2; posterior lateral tibial plateau, left stifle joint 
 
From the individual parameters assessed, the biggest difference between the bupivacaine injected 
joints and the saline control joints, was found in safranin-O staining, with a 22% reduction in 
staining in the bupivacaine group (p = 0.381). Figure 2.12 is an example of normal safranin-O 
staining from the control, left stifle joint. 
 





Fig. 2.12: Sheep 1; anterior lateral femoral condyle, left stifle joint 
 
Complete loss of safranin-O staining was found in a bupivacaine injected right stifle joint, as shown 






















3.1 LITERATURE REVIEW 
 
Numerous in vitro and in vivo studies confirmed the chondrotoxic effect of bupivacaine. 
Ropivacaine may be the least toxic local anesthetic agent for intra-articular use.18 One in vivo study 
suggested that bupivacaine’s enantiomer, levobupivacaine, may be safe.20 In this study the time 
from intra-articular levobupivacaine administration and sampling of the cartilage for histological 
analysis was only 21 days, which could falsely increase the likelihood of negative results as 
changes become more prevalent at longer intervals after administration.11 One in vitro study even 
found levobupivacaine to be more toxic to chondrocytes than bupivacaine.19 The chondrotoxic 
effect of bupivacaine is a uniform finding over numerous species, as investigated in dogs, rats and 
humans.13-15 
 
The addition of epinephrine to intra-articular bupivacaine did not increase the risk of 
chondrotoxicity in an in vivo rat model.12 In contrast, in an in vitro study on human chondrocytes, 
the addition of epinephrine did cause more chondrolysis.13 Cartilage cells in joint cavities have a 
very limited blood supply. Epinephrine is a very strong vasoconstrictor. This should caution against 
its use as additive to intra-articular bupivacaine. 
   
The duration of exposure of chondrocytes to bupivacaine has proved to increase cartilage damage.14 
One in vitro study suggested that an infusion time of less than 48 hours may be safe.13 
Chondrotoxicity due to bupivacaine is also dependent on the intra-articular dosage used.16 The total 
dosage of bupivacaine is a product of the concentration and volume used. By reducing either the 
volume or the concentration, one can therefore limit the total dosage administered. 
 
3.2 SINGLE DOSE INTRA-ARTICULAR BUPIVACAINE PILOT STUDY 
 
Total Modified Mankin Scores were calculated in both the knee and stifle joints, after 
administration of the supra-normal and therapeutic dosages of 0.5% bupivacaine respectively. These 
were compared to 0.9% saline administration in the contralateral joints, which served as controls. 
With both dosages, the total scores were higher in the bupivacaine group as compared to the saline 
group. Statistical analysis of the different parameters, namely, articular surface integrity, cloning 
formation, cellularity and safranin-O staining, also proved to be higher in the bupivacaine groups, 
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except for the safranin-O staining in the knee joints (-5,5%). Articular surface integrity (-8.6%) and 
cellularity (-1.7%) in the stifle joints were also higher in the saline groups.  
 
Statistical analysis could not conclude a significant difference between the groups, as the 95% 
confidence intervals always included 0. This was only a pilot study, with a very small sample size, 
limited by the costs involved. A power analysis of the pilot study is also not applicable. It is 
therefore difficult to draw conclusions with the limited data available. Bigger sample sizes will 
narrow the 95% confidence interval and improve interpretation. 
 
If we are to assume that equal anatomical samples from different legs are uncorrelated, according to 
Wilcoxon signed-rank test, there was a significant difference between the bupivacaine and saline 
groups in safranin-O staining (p=0.014) as illustrated in table 3.1.  Higher scores were observed in 
the right stifle joints (bupivacaine group) when compared to the left stifle joints (saline group). 




Wilcoxin signed-rank test 








We therefore conclude that single dose intra-articular bupivacaine may be chondrotoxic, but we 
need a bigger sample size to confirm our strong suspicion.  
 
 
3.3 PATHOPHYSIOLOGY OF BUPIVACAINE CHONDROTOXCICITY 
 
The exact mechanism of bupivacaine chondrotoxicity is unclear. A proposed mechanism is 
disruption of the cell membrane that might cause acute necrosis.  This phenomenon increases with 
increased fat solubility, which is a known characteristic of bupivacaine. Mitochondrial function may 
also be affected, by disrupting the mitochondrial transmembrane potential, leading to less ATP 
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production.  Alterations in mitochondrial DNA then lead to chondrocyte apoptosis.11 The agent must 
diffuse through the intercellular matrix to exert its chondrotoxic effect. Disruption of the superficial 
layer of cartilage, by example inserting anchor sutures by the surgeon, can increase the risk of 
chondrotoxicity by damaging the protective barrier of chondrocytes. An intra-articular injectate can 
then infiltrate the intercellular proteoglycan matrix of the cartilage, with less resistance, and cause 
its toxic effects to chondrocytes. 
 
Cartilage, compared to other tissues, has limited ability to heal and regenerate itself.  Once an insult 
has occurred, a long term effect becomes possible. Loss of functional cells will result in loss of 
extracellular matrix and collagen production, which plays a vital role in the integrity of the cartilage 
tissue.17 
 
Because of uncertainty concerning the mechanism of action of bupivacaine chondrotoxicity, can 
one safely assume cause and effect? In a meta-analysis by Matsen, et al.11, it was shown that there is 
indeed “strong association, consistency, specificity, temporal relationship, biological gradient and 
plausibility, overall coherence of evidence, good experimental evidence and analogy”. Matsen 
therefore concluded that bupivacaine does cause chondrocyte damage.11 
 
3.4 ALTERNATIVES TO INTRA-ARTICULAR BUPIVACAINE 
 
All local anesthetics have been implicated in chondrocyte death. Ropivacaine seems to be the least 
toxic.18 Recently, magnesium, a N-methyl-D-aspartate (NMDA) receptor antagonist, has been used 
as part of a multimodal analgesic regime for joint pain. NMDA receptors have been found on intra-
articular surfaces and Bondok et al.26 showed that intra-articular magnesium is an effective 
alternative to intra-articular bupivacaine.26 Magnesium not only has analgesic properties but also 
has chondro-proliferative properties.27 Interestingly, Baker et al.16 found that 10% magnesium 
attenuated the chondrotoxic effects of local anesthetics.16 
 
Intra-articular steroids have proven to increase the risk of septic arthritis and may even have a 
synergistic toxic effect on chondrocytes when combined with local anesthetics.3, 28 
 
The data on the use of intra-articular morphine has been conflicting.  In a qualitative review of 46 
randomized controlled trials done by Rosseland et al.29 in 2005, the conclusion was that intra-
articular morphine was an ineffective analgesic for joint surgery.29 Previous studies used small 
dosages (example 1 mg) of intra-articular morphine, so Garcia et al.30 undertook a randomized 
Stellenbosch University  https://scholar.sun.ac.za
24 
 
controlled trial, in 2010, on 50 patients comparing 10 mg intra-articular morphine with intra-
articular normal saline. A significant reduction in rescue analgesia was observed in the morphine 
group (p = 0.0001). The time to request additional analgesia was also longer in the morphine group 
(p = 0.0166). Post-operative pain scores were also reduced at 2 and 6 hours in the morphine 
group.30 
 
Intra-articular alpha 2 agonists such as clonidine have also been used with good effect, but more 


































Intra-articular bupivacaine is common practice in joint analgesia. It's efficacy as analgesic shows 
good response, but the risk involved is undoubtedly irreversible, and potentially disabling, 
chondrolysis. Bupivacaine’s intra-articular chondrotoxic effect is time, concentration and dose 
dependent. Using intra-articular bupivacaine infusions increases the risk of chondrocyte toxicity. 
Single dose intra-articular bupivacaine may also be significantly chondrotoxic. Chu et al.23 showed 
a statistically significant 50% reduction in chondrocyte density after a single dose of intra-articular 
bupivacaine in rats.  From our pilot study done on 4 sheep, the overall impression was increased 
chondrotoxicity in the bupivacaine groups, but statistical significance could not be proven due to a 
small sample size. 
 
The addition of intra-articular magnesium sulphate appears to attenuate the chondrotoxic effect of 
local anesthetics and magnesium has a proliferative effect on chondrocytes. High dose intra-
articular morphine and intra-articular clonidine may prove beneficial as analgesics for joint surgery, 
but more data is needed. Poor integrity of the articular surface increases the risk of chondrocyte 























1. APPENDIX A: Monitoring sheet for sheep wellbeing 
 
A case controlled experiment to evaluate the in vivo effects of single dose intra-






Date    : 
 






    Normal      Swelling     Effusion   Induration Tenderness 
Right knee joint 
Left knee joint 
Right stifle joint 
Left stifle joint 
 
Chronic complications 








Reviewed by: ..........................      ................................ 
          Signature 
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Sheep 1 : Front Knee Os Carpi Ulnare Right 1 1 1 2 5
Os carpi intermedium Right 1 1 1 2 5
Os Carpi Radiale Right 1 1 0 1 3
Os Carpale quartum Right 2 1 1 1 5
Os Carpale tertium Right 0 1 1 1 3
Total 21
Os Carpi Ulnare Left 0 1 3 1 5
Os carpi intermedium Left 0 1 3 0 4
Os Carpi Radiale Left 0 1 1 1 3
Os Carpale quartum Left 1 1 0 3 5
Os Carpale tertium Left 0 0 0 0 0
Total 17
Sheep 2 : Front Knee Os Carpi Ulnare Right 3 1 1 0 5
Os carpi intermedium Right 0 1 1 1 3
Os Carpi Radiale Right 1 1 1 0 3
Os Carpale quartum Right Sample not suitable for analysis
Os Carpale tertium Right 1 1 1 0 3
Total 14
Os Carpi Ulnare Left 3 1 2 1 7
Os carpi intermedium Left 0 1 2 2 5
Os Carpi Radiale Left 3 1 1 0 5
Os Carpale quartum Left
Os Carpale tertium Left 2 0 1 1 4
Total 21
Sheep 3 : Front Knee Os Carpi Ulnare Right 4 2 2 2 10
Os carpi intermedium Right 3 1 2 4 10
Os Carpi Radiale Right 0 1 0 2 3
Os Carpale quartum Right 2 1 2 2 7
Os Carpale tertium Right 1 1 2 1 5
Total 35
Os Carpi Ulnare Left 0 0 1 1 2
Os carpi intermedium Left 1 0 1 2 4
Os Carpi Radiale Left 2 0 1 2 5
Os Carpale quartum Left 0 1 1 2 4
Os Carpale tertium Left 0 0 1 0 1
Total 16
Sheep 4 : Front Knee Os Carpi Ulnare Right 3 0 1 1 5
Os carpi intermedium Right 0 0 0 0 0
Os Carpi Radiale Right 0 0 0 0 0
Os Carpale quartum Right 0 0 3 2 5
Os Carpale tertium Right 3 0 3 1 7
Total 17
Os Carpi Ulnare Left 2 1 1 1 5
Os carpi intermedium Left 0 0 0 2 2
Os Carpi Radiale Left 0 1 3 2 6
Os Carpale quartum Left 0 1 0 1 2
Os Carpale tertium Left 3 1 1 2 7
Total 22  
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Sheep 1: Stifle joint Ant Patella Right 1 0 1 0 2
Post Patella Right 1 1 0 0 2
Ant Femoral Grove Right 0 0 1 1 2
Central Femoral Grove Right 1 0 0 1 2
Post Fem Grove Right 1 1 0 1 3
Ant Lat Fem Grove Right 0 0 0 1 1
Post Lat Fem Condyle Right 0 0 0 0 0
Ant Med Fem Condyle Right 0 0 0 0 0
Post Med Fem Condyle Right 1 0 0 2 3
Ant Lat T ib Plateau Right 1 0 0 2 3
Post Lat T ib Plateau Right Sample not suitable for analysis
Cent Lat T ib Plateau Right 0 0 0 1 1
Ant Med T ib Plateau Right 1 1 0 1 3
Post Med T ib Plateau Right 1 1 0 0 2
Cent T ib Plateau Right 2 1 1 3 7
Total 31
Ant Patella Left 0 1 1 1 3
Post Patella Left 1 0 0 0 1
Ant Femoral Grove Left 0 0 0 0 0
Central Femoral Grove Left 1 1 1 1 4
Post Fem Grove Left 0 1 2 2 5
Ant Lat Fem Grove Left 0 0 0 0 0
Post Lat Fem Condyle Left 0 0 0 3 3
Ant Med Fem Condyle Left 1 1 1 1 4
Post Med Fem Condyle Left 0 0 0 0 0
Ant Lat T ib Plateau Left 0 0 1 0 1
Post Lat T ib Plateau Left
Cent Lat T ib Plateau Left 0 0 0 3 3
Ant Med T ib Plateau Left 0 1 0 1 2
Post Med T ib Plateau Left 0 0 1 3 4
Cent T ib Plateau Left 0 0 0 2 2






















Sheep 2: Stifle joint Ant Patella Right 0 0 0 1 1
Post Patella Right 1 0 0 2 3
Ant Femoral Grove Right 2 0 1 0 3
Central Femoral Grove Right 0 1 3 1 5
Post Fem Grove Right 0 0 0 1 1
Ant Lat Fem Grove Right 1 0 0 1 2
Post Lat Fem Condyle Right 0 0 0 0 0
Ant Med Fem Condyle Right 1 1 1 2 5
Post Med Fem Condyle Right 0 0 0 2 2
Ant Lat T ib Plateau Right 1 1 1 3 6
Post Lat T ib Plateau Right 3 1 1 5 10
Cent Lat T ib Plateau Right 0 1 1 0 2
Ant Med T ib Plateau Right 0 1 0 2 3
Post Med T ib Plateau Right 3 1 1 0 5
Cent T ib Plateau Right 4 1 2 2 9
Total 57
Ant Patella Left 0 1 0 2 3
Post Patella Left 3 1 1 2 7
Ant Femoral Grove Left 1 1 1 0 3
Central Femoral Grove Left 1 1 3 1 6
Post Fem Grove Left 0 1 0 1 2
Ant Lat Fem Grove Left 2 1 1 5 9
Post Lat Fem Condyle Left 0 0 0 0 0
Ant Med Fem Condyle Left 2 0 0 1 3
Post Med Fem Condyle Left 4 1 0 3 8
Ant Lat T ib Plateau Left 0 0 0 0 0
Post Lat T ib Plateau Left 3 1 2 5 11
Cent Lat T ib Plateau Left 3 1 1 2 7
Ant Med T ib Plateau Left 2 1 1 2 6
Post Med T ib Plateau Left 2 1 3 1 7
Cent T ib Plateau Left 3 1 0 3 7




















Sheep 3: Stifle joint Ant Patella Right 1 0 0 3 4
Post Patella Right 0 1 3 3 7
Ant Femoral Grove Right 0 1 3 2 6
Central Femoral Grove Right 0 0 1 5 6
Post Fem Grove Right 0 0 0 4 4
Ant Lat Fem Grove Right 0 0 1 2 3
Post Lat Fem Condyle Right 1 0 2 3 6
Ant Med Fem Condyle Right 2 0 1 2 5
Post Med Fem Condyle Right 2 1 0 2 5
Ant Lat T ib Plateau Right 2 1 1 3 7
Post Lat T ib Plateau Right 2 1 0 5 8
Cent Lat T ib Plateau Right 2 0 0 5 7
Ant Med T ib Plateau Right 1 0 1 1 3
Post Med T ib Plateau Right 2 1 1 5 9
Cent T ib Plateau Right 0 0 0 1 1
Total 81
Ant Patella Left 0 0 0 1 1
Post Patella Left 0 0 0 1 1
Ant Femoral Grove Left 1 1 2 2 6
Central Femoral Grove Left 1 0 3 1 5
Post Fem Grove Left 0 0 0 2 2
Ant Lat Fem Grove Left 3 0 0 0 3
Post Lat Fem Condyle Left 3 1 0 2 6
Ant Med Fem Condyle Left 1 0 0 1 2
Post Med Fem Condyle Left 2 0 0 1 3
Ant Lat T ib Plateau Left 1 1 0 0 2
Post Lat T ib Plateau Left 1 1 0 5 7
Cent Lat T ib Plateau Left 0 0 1 0 1
Ant Med T ib Plateau Left 1 0 0 0 1
Post Med T ib Plateau Left 0 1 1 0 2
Cent T ib Plateau Left 3 1 0 0 4

















Sheep 4: Stifle joint Ant Patella Right 1 0 0 5 6
Post Patella Right 0 0 3 1 4
Ant Femoral Grove Right 0 1 1 1 3
Central Femoral Grove Right 0 1 1 2 4
Post Fem Grove Right 1 0 0 2 3
Ant Lat Fem Grove Right 2 1 1 2 6
Post Lat Fem Condyle Right 0 1 1 0 2
Ant Med Fem Condyle Right 3 1 3 0 7
Post Med Fem Condyle Right 1 1 1 1 4
Ant Lat T ib Plateau Right 1 1 0 2 4
Post Lat T ib Plateau Right 3 2 0 2 7
Cent Lat T ib Plateau Right 0 2 0 2 4
Ant Med T ib Plateau Right 1 1 0 2 4
Post Med T ib Plateau Right 1 1 0 5 7
Cent T ib Plateau Right 0 3 0 0 3
Total 68
Ant Patella Left 1 0 1 2 4
Post Patella Left 3 1 0 0 4
Ant Femoral Grove Left 1 1 3 0 5
Central Femoral Grove Left 3 0 0 1 4
Post Fem Grove Left 0 0 1 0 1
Ant Lat Fem Grove Left 1 0 0 1 2
Post Lat Fem Condyle Left 2 0 0 0 2
Ant Med Fem Condyle Left 1 0 0 0 1
Post Med Fem Condyle Left 1 1 3 2 7
Ant Lat T ib Plateau Left 3 1 0 0 4
Post Lat T ib Plateau Left 5 3 0 2 10
Cent Lat T ib Plateau Left 0 0 1 2 3
Ant Med T ib Plateau Left 1 2 0 2 5
Post Med T ib Plateau Left 5 3 0 1 9
Cent T ib Plateau Left 2 1 1 0 4
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